Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders
Authors
Keywords
Checkpoint blockade, Peripheral T-cell lymphoma, Cutaneous T-cell lymphoma, PD-L1
Journal
Journal for ImmunoTherapy of Cancer
Volume 4, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-12-13
DOI
10.1186/s40425-016-0201-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents
- (2016) Sumana Devata et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Candidate driver genes involved in genome maintenance and DNA repair in Sézary syndrome
- (2016) Wesley J. Woollard et al. BLOOD
- Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas
- (2016) K. Georgiou et al. BLOOD
- Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?
- (2016) Javeed Iqbal et al. BLOOD REVIEWS
- The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era
- (2016) Yngvild Nuvin Blaker et al. BRITISH JOURNAL OF HAEMATOLOGY
- Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment
- (2016) Zhenyu Zhong et al. CELL
- Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia
- (2016) A. Polk et al. CLINICAL CANCER RESEARCH
- HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
- (2016) Hong Zheng et al. CLINICAL CANCER RESEARCH
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
- (2016) Keisuke Kataoka et al. NATURE
- Tumor-induced stromal reprogramming drives lymph node transformation
- (2016) Angela Riedel et al. NATURE IMMUNOLOGY
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Histone deacetylase inhibitors as immunomodulators in cancer therapeutics
- (2016) Li Shen et al. Epigenomics
- B cell regulation of the anti-tumor response and role in carcinogenesis
- (2016) Marc Schwartz et al. Journal for ImmunoTherapy of Cancer
- A three-signal model of T-cell lymphoma pathogenesis
- (2015) Ryan A. Wilcox AMERICAN JOURNAL OF HEMATOLOGY
- PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia
- (2015) F. McClanahan et al. BLOOD
- Mogamulizumab: 2 birds, 1 stone
- (2015) R. A. Wilcox BLOOD
- Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma
- (2015) A. H. Rook et al. BLOOD
- Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma
- (2015) M. Duvic et al. BLOOD
- The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma
- (2015) T. E. Witzig et al. BLOOD
- Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma
- (2015) J. Kiyasu et al. BLOOD
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
- (2015) G. Gorgun et al. CLINICAL CANCER RESEARCH
- mTOR: a pharmacologic target for autophagy regulation
- (2015) Young Chul Kim et al. JOURNAL OF CLINICAL INVESTIGATION
- Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
- (2015) Owen A. O'Connor et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
- (2015) Andrew B Sharabi et al. LANCET ONCOLOGY
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- Genomic landscape of cutaneous T cell lymphoma
- (2015) Jaehyuk Choi et al. NATURE GENETICS
- The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome
- (2015) Ana Carolina da Silva Almeida et al. NATURE GENETICS
- Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2
- (2015) Alexander Ungewickell et al. NATURE GENETICS
- Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes
- (2015) Linghua Wang et al. NATURE GENETICS
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
- (2015) Idit Sagiv-Barfi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK–STAT pathway in Sézary syndrome
- (2015) Mark J. Kiel et al. Nature Communications
- Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study
- (2015) Colm Keane et al. Lancet Haematology
- GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features
- (2014) T. Wang et al. BLOOD
- Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy
- (2014) Charlotte F. M. Hughes et al. BLOOD
- Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma
- (2014) J. Iqbal et al. BLOOD
- Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
- (2014) Carola H. Ries et al. CANCER CELL
- Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sezary Syndrome
- (2014) X. Ni et al. CLINICAL CANCER RESEARCH
- mTOR signaling, Tregs and immune modulation
- (2014) Nicole M Chapman et al. Immunotherapy
- Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
- (2014) Michinori Ogura et al. JOURNAL OF CLINICAL ONCOLOGY
- Gain-of-functionCCR4mutations in adult T cell leukemia/lymphoma
- (2014) Masao Nakagawa et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Discovery and saturation analysis of cancer genes across 21 tumour types
- (2014) Michael S. Lawrence et al. NATURE
- A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma
- (2014) Hae Yong Yoo et al. NATURE GENETICS
- Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas
- (2014) Teresa Palomero et al. NATURE GENETICS
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas
- (2014) R Briski et al. Blood Cancer Journal
- Personalized treatment of Sézary syndrome by targeting a novelCTLA4:CD28fusion
- (2014) Aleksandar Sekulic et al. Molecular Genetics & Genomic Medicine
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- (2013) J. A. Dubovsky et al. BLOOD
- Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy
- (2013) S. Mok et al. CANCER RESEARCH
- Molecular mechanisms of ATP secretion during immunogenic cell death
- (2013) I Martins et al. CELL DEATH AND DIFFERENTIATION
- Prevalence and clinical implications of chromothripsis in cancer genomes
- (2013) Wigard P. Kloosterman et al. CURRENT OPINION IN ONCOLOGY
- A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial
- (2013) Franck Morschhauser et al. EUROPEAN JOURNAL OF CANCER
- Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma
- (2013) Kelly A. Cycon et al. IMMUNOLOGY
- Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
- (2013) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors
- (2013) Vivien Mak et al. JOURNAL OF CLINICAL ONCOLOGY
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- (2013) Jason R Westin et al. LANCET ONCOLOGY
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Pan-cancer patterns of somatic copy number alteration
- (2013) Travis I Zack et al. NATURE GENETICS
- CSF-1R inhibition alters macrophage polarization and blocks glioma progression
- (2013) Stephanie M Pyonteck et al. NATURE MEDICINE
- Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
- (2013) D. Sugiyama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- Histone/protein deacetylases and T-cell immune responses
- (2012) T. Akimova et al. BLOOD
- The expanding role(s) of eosinophils in health and disease
- (2012) E. A. Jacobsen et al. BLOOD
- Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer
- (2012) A. G. Ramsay et al. BLOOD
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
- (2012) M. R. Green et al. CLINICAL CANCER RESEARCH
- The B7 Homologues and their Receptors in Hematologic Malignancies
- (2012) Ryan A. Wilcox et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
- (2012) Bertrand Coiffier et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Chemokine Receptor CCR4 in Adult T-Cell Leukemia-Lymphoma and Other T-Cell Lymphomas
- (2012) Kensei Tobinai et al. Current Hematologic Malignancy Reports
- Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management
- (2011) Ryan A. Wilcox AMERICAN JOURNAL OF HEMATOLOGY
- Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling
- (2011) D. A. Hume et al. BLOOD
- In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study
- (2011) Y. H. Kim et al. BLOOD
- mTOR Kinase Inhibitor AZD8055 Enhances the Immunotherapeutic Activity of an Agonist CD40 Antibody in Cancer Treatment
- (2011) Q. Jiang et al. CANCER RESEARCH
- Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
- (2011) M. Michaud et al. SCIENCE
- Restoration of peripheral blood T cell repertoire complexity during remission in advanced cutaneous T cell lymphoma
- (2010) Kei-ichi Yamanaka et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Increased Programmed Death-1 Expression on CD4+ T Cells in Cutaneous T-Cell Lymphoma
- (2010) Sara Samimi et al. ARCHIVES OF DERMATOLOGY
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal
- (2010) Nita Sally Agar et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2
- (2009) M. Gupta et al. BLOOD
- Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells
- (2009) R. A. Wilcox et al. BLOOD
- B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders
- (2009) R. A. Wilcox et al. BLOOD
- Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824
- (2009) D. D. Vo et al. CANCER RESEARCH
- Ikaros Is a Regulator of Il10 Expression in CD4+ T Cells
- (2009) S. E. Umetsu et al. JOURNAL OF IMMUNOLOGY
- Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells
- (2008) L. Wu et al. CLINICAL CANCER RESEARCH
- CC-4047 promotes Th1 cell differentiation and reprograms polarized human Th2 cells by enhancing transcription factor T-bet
- (2008) Weiming Xu et al. CLINICAL IMMUNOLOGY
- International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes
- (2008) JOURNAL OF CLINICAL ONCOLOGY
- Transcriptional Modulation Using HDACi Depsipeptide Promotes Immune Cell-Mediated Tumor Destruction of Murine B16 Melanoma
- (2008) Takashi Murakami et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started